Expressão de ERCC1, NF-kB e transglutaminase como fatores preditivos de resposta à quimioterapia em pacientes com câncer de testículo

• Autor(a) principal: Azambuja, Alan Arrieira
• Data de Publicação: 2016
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da PUC_RS
• Texto Completo: http://tede2.pucrs.br/tede2/handle/tede/7187
• topic: NEOPLASIAS UROLÓGICAS; TESTÍCULO - PATOLOGIA; QUIMIOTERAPIA; MEDICINA; CIENCIAS DA SAUDE::MEDICINA

Tumors of testicular germ cells (TGCT) are associated with a high cure rate, and are very sensitive to platinum based chemotherapy. Different mechanisms are related to resistance to chemotherapy and higher recurrence. We evaluate the risk of recurrence related to expression of nuclear factor kappa- B (NF-κB), excision repair cross-complementation group 1 (ERCC1) e transglutaminase 2 (TG2), in patients with TGCT treated with platinum combinations. Seventy-six patients were evaluated with TGCT treated with platinum-based chemotherapy 2001 to 2011 in the Department of Oncology of the HSL/PUCRS. Immunohistochemistry analysis was performed and expression correlated with clinical and laboratory data. Fifty patients were included in the group, mean age was 28.4 (18 to 45), 68% non-seminoma histology. All patients were treated with BEP or EP. Multivariate analysis identified that positive expressions of NF-κB and ERCC1 are independent risk factors for higher recurrence TGCT after chemotherapy (RR 3.16 and 2.96). There was no significance in TG2 cases. In conclusion, expression of ERCC1 and NF-κB give much worse prognosis for relapse to patients with TGCT treated with platinumbased chemotherapy. They may represent markers that predict poor clinical outcome and response to chemotherapy.